论文部分内容阅读
目的:探索炎症性肠病患者白细胞介素-23(interleukin-23,IL-23)受体基因多态性与临床治疗效果的关系。方法:通过对80例炎症性肠病患者IL-23受体基因多态性位点rs11209032、rs11805303、rs17375018的检测,结合患者经水杨酸制剂以及激素治疗后症状缓解情况,分析炎症性肠病患者IL-23受体基因多态性与临床疗效的关系。结果:IL-23受体单核苷酸rs11209032位点的GG与GA、GG与AA基因型患者的缓解率差异有统计学意义(P<0.05),G与A等位基因患者的症状缓解率差异有统计学意义(P<0.05)。rs11805303位点C与T等位基因患者加用激素后,症状缓解率差异有统计学意义(P<0.05)。结论:该研究提示rs11209032基因型和等位基因的突变,会降低患者对水杨酸制剂的敏感性,而rs11805303等位基因突变的患者,对激素治疗比较敏感。
Objective: To explore the relationship between interleukin-23 (IL-23) receptor gene polymorphism and clinical outcome in patients with inflammatory bowel disease. Methods: The polymorphisms of rs11209032, rs11805303 and rs17375018 of IL-23 receptor gene in 80 patients with inflammatory bowel disease were analyzed. Combined with the salicylic acid preparation and the symptom relief after hormone therapy, the inflammatory bowel disease Relationship between IL-23 receptor gene polymorphism and clinical efficacy in patients. Results: There was a significant difference in the remission rate between GG and GA, GG and AA genotypes at SNP rs11209032 of IL-23 receptor (P <0.05), and the rate of symptom relief in G and A alleles The difference was statistically significant (P <0.05). rs11805303 site C and T allele patients with hormones, the difference was statistically significant (P <0.05). Conclusions: This study suggests that mutations in rs11209032 genotypes and alleles may reduce the sensitivity of patients to salicylate formulations, whereas patients with rs11805303 alleles are more susceptible to hormone therapy.